90 Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study

Br J Haematol. 2020 Apr;189(1):e6-e9. doi: 10.1111/bjh.16404. Epub 2020 Jan 13.
No abstract available

Keywords: 90Y-ibritumomab tiuxetan; MALT lymphoma; extra-nodal marginal zone B-cell lymphoma; relapsed; treatment-naïve.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / drug therapy*
  • Lymphoma, B-Cell, Marginal Zone / mortality*
  • Male
  • Middle Aged
  • Survival Rate

Substances

  • Antibodies, Monoclonal
  • ibritumomab tiuxetan